Developing Innovative Ligands for Nuclear Receptors to Eradicate Cancer Relapse
The aim of the Marie Sklodowska-Curie Doctoral Network “eRaDicate” is to develop new therapies against cancer stem cell-driven relapse and metastasis. Our 11 doctoral candidates (DCs) of eRaDicate will be trained not only to perform original and independent research on an internationally competitive level, but will also be endowed with a creative, critical and entrepreneurial mindset, coupled with persistence in following their objectives.
Recruitment of our fellows has been completed. They will start their contracts in the fall of 2024. Watch this space for updates and an introduction to our fellows.
News
Dominika Mangabat’s secondment at the CiMUS
In the days between May 12th and June 13th this year, I had the opportunity to carry out a five-week secondment at the Centre for Research in Molecular Medicine and Chronic Diseases (CiMUS), of the University of Santiago de Compostela (USC) …
Magda Góis and Dominika Mangabat’s secondment at J&J Ireland
In the days from July 7th to July 11th, we, Magda Góis and Dominika Mangabat, took part in a shared one-week secondment at the Johnson & Johnson Innovative Medicine site…
Agnes Graf’s secondment to the Medical University of Vienna
10 months into my PhD, I did my first Secondment at the Medical University of Vienna (Austria) working with…
Consortium
The eRaDicate consortium consists of eight academic and one industrial and beneficiaries, as well as twelve associated partners to provide training and secondments.
Beneficiaries
Associated Partners
